These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 32015192)

  • 21. Exploring the Attractiveness of New Psychoactive Substances (NPS) among Experienced Drug Users.
    van Amsterdam JG; Nabben T; Keiman D; Haanschoten G; Korf D
    J Psychoactive Drugs; 2015; 47(3):177-81. PubMed ID: 26098724
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of new psychoactive substances (NPS) in young people and their role in mental health care: a systematic review.
    Orsolini L; Chiappini S; Corkery JM; Guirguis A; Papanti D; Schifano F
    Expert Rev Neurother; 2019 Dec; 19(12):1253-1264. PubMed ID: 31503507
    [No Abstract]   [Full Text] [Related]  

  • 23. Negative consequences of novel psychoactive substances use among the Polish users.
    Wieczorek Ł; Bujalski M; Dąbrowska K
    Psychiatr Pol; 2021 Apr; 55(2):447-469. PubMed ID: 34365491
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Emergence of novel psychoactive substances among clients of a needle exchange program in Budapest, Hungary].
    Rácz J; Csák R
    Orv Hetil; 2014 Aug; 155(35):1383-94. PubMed ID: 25161053
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of the UK Psychoactive Substances Act 2016 on episodes of toxicity related to new psychoactive substances as reported to the National Poisons Information Service. A time series analysis.
    Al-Banaa I; Hawkins L; Hill SL; Lupton DJ; Jackson G; Sandilands EA; Bradberry SM; Thompson JP; Rushton S; Thomas SHL
    Int J Drug Policy; 2020 Mar; 77():102672. PubMed ID: 32032867
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Are government-approved products containing new psychoactive substances perceived to be safer and more socially acceptable than alcohol, tobacco and illegal drugs? Findings from a survey of police arrestees in New Zealand.
    Rychert M; Wilkins C; Parker K; Witten K
    Drug Alcohol Rev; 2018 Mar; 37(3):406-413. PubMed ID: 29285812
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The drug situation in Europe: an overview of data available on illicit drugs and new psychoactive substances from European monitoring in 2015.
    Mounteney J; Griffiths P; Sedefov R; Noor A; Vicente J; Simon R
    Addiction; 2016 Jan; 111(1):34-48. PubMed ID: 26419329
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characteristics of the use of 3-MMC and other new psychoactive drugs in Slovenia, and the perceived problems experienced by users.
    Sande M
    Int J Drug Policy; 2016 Jan; 27():65-73. PubMed ID: 25908121
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of the COVID-19 pandemic on the use of the performance-enhancing drugs.
    Negro F; Di Trana A; Marinelli S
    Acta Biomed; 2022 Jan; 92(6):e2021401. PubMed ID: 35075058
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How to ask about the use of new psychoactive substances to increase the validity of results in self-report prevalence surveys.
    Drapalova E; Belackova V; Cadet-Taïrou A
    Drug Alcohol Rev; 2020 Mar; 39(3):278-286. PubMed ID: 32078202
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monitoring psychoactive substance use at six European festivals through wastewater and pooled urine analysis.
    Bijlsma L; Celma A; Castiglioni S; Salgueiro-González N; Bou-Iserte L; Baz-Lomba JA; Reid MJ; Dias MJ; Lopes A; Matias J; Pastor-Alcañiz L; Radonić J; Turk Sekulic M; Shine T; van Nuijs ALN; Hernandez F; Zuccato E
    Sci Total Environ; 2020 Jul; 725():138376. PubMed ID: 32298891
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HCV prevalence and risk behaviours among injectors of new psychoactive substances in a risk environment in Hungary-An expanding public health burden.
    Tarján A; Dudás M; Wiessing L; Horváth G; Rusvai E; Tresó B; Csohán Á
    Int J Drug Policy; 2017 Mar; 41():1-7. PubMed ID: 27984762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patterns and correlates of new psychoactive substance use in a sample of Australian high school students.
    Champion KE; Teesson M; Newton NC
    Drug Alcohol Rev; 2016 May; 35(3):338-44. PubMed ID: 26194894
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug trends and harm related to new psychoactive substances (NPS) in Sweden from 2010 to 2016: Experiences from the STRIDA project.
    Helander A; Bäckberg M; Beck O
    PLoS One; 2020; 15(4):e0232038. PubMed ID: 32324788
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New psychoactive substances: Current health-related practices and challenges in responding to use and harms in Europe.
    Pirona A; Bo A; Hedrich D; Ferri M; van Gelder N; Giraudon I; Montanari L; Simon R; Mounteney J
    Int J Drug Policy; 2017 Feb; 40():84-92. PubMed ID: 27956184
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel psychoactive substances as a novel challenge for health professionals: results from an Italian survey.
    Simonato P; Corazza O; Santonastaso P; Corkery J; Deluca P; Davey Z; Blaszko U; Schifano F
    Hum Psychopharmacol; 2013 Jul; 28(4):324-31. PubMed ID: 23881880
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monitoring new psychoactive substances: Exploring the contribution of an online discussion forum.
    Rhumorbarbe D; Morelato M; Staehli L; Roux C; Jaquet-Chiffelle DO; Rossy Q; Esseiva P
    Int J Drug Policy; 2019 Nov; 73():273-280. PubMed ID: 30967328
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New Psychoactive Substances and receding COVID-19 pandemic: really going back to "normal"?
    Napoletano S; Basile G; Lo Faro AF; Negro F
    Acta Biomed; 2022 May; 93(2):e2022186. PubMed ID: 35545997
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Taking the cat-and-mouse game to the next level: different perspectives on the introduction of the German New Psychoactive Substances Act.
    Kühnl R; Aydin D; Horn S; Olderbak S; Verthein U; Kraus L
    Harm Reduct J; 2022 Nov; 19(1):122. PubMed ID: 36329471
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How preclinical studies have influenced novel psychoactive substance legislation in the UK and Europe.
    Santos-Toscano R; Guirguis A; Davidson C
    Br J Clin Pharmacol; 2020 Mar; 86(3):452-481. PubMed ID: 32045495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.